ChromaDex Co. (NASDAQ:CDXC) CFO Buys $21,395.52 in Stock

ChromaDex Co. (NASDAQ:CDXC) CFO Ozan Pamir acquired 2,907 shares of ChromaDex stock in a transaction that occurred on Friday, November 22nd. The stock was bought at an average cost of $7.36 per share, with a total value of $21,395.52. Following the acquisition, the chief financial officer now directly owns 2,907 shares of the company’s stock, valued at approximately $21,395.52. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

ChromaDex Stock Performance

Shares of NASDAQ:CDXC opened at $7.64 on Thursday. The stock has a market capitalization of $583.54 million, a price-to-earnings ratio of 764.76 and a beta of 1.88. ChromaDex Co. has a 1-year low of $1.32 and a 1-year high of $7.89. The company has a 50 day moving average price of $4.86 and a 200 day moving average price of $3.67.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The business had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period last year, the company posted ($0.01) EPS. On average, sell-side analysts expect that ChromaDex Co. will post 0.04 EPS for the current fiscal year.

Institutional Trading of ChromaDex

Hedge funds have recently bought and sold shares of the company. WINTON GROUP Ltd acquired a new stake in shares of ChromaDex during the second quarter valued at approximately $597,000. Bank of New York Mellon Corp lifted its holdings in shares of ChromaDex by 170.0% in the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after purchasing an additional 119,915 shares in the last quarter. BSW Wealth Partners acquired a new stake in shares of ChromaDex in the third quarter worth $324,000. BNP Paribas Financial Markets raised its position in ChromaDex by 1,885.7% during the third quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock valued at $267,000 after buying an additional 69,582 shares during the period. Finally, State Street Corp lifted its stake in ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after acquiring an additional 62,692 shares in the last quarter. 15.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Roth Mkm boosted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 18th. Finally, HC Wainwright lifted their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.